Psychedelic: GH Research, Compass Pathways report earnings results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, ...
Investing5h
Compass Therapeutics shares rise on pipeline progress
BOSTON - Compass Therapeutics, Inc. (NASDAQ: CMPX) shares gained 2.7% after the clinical-stage oncology company reported progress across its pipeline and provided a business update for 2024. While the ...
Compass Therapeutics’ (CMPX) “Buy” Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...
kalkinemedia15h
Can Maze Therapeutics Transform Genetic Medicine?
Highlights,Maze Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicines for renal, ...
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) to a strong-buy rating in a report released ...